GW01-200 / Groovy Medicine - LARVOL DELTA

GW01-200-01: A Phase I Trial of GW01-200 Tablets in Subjects With Advanced Tumors (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Groovy Medicine (Hangzhou) Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Hematological Malignancies • Oncology